USANA Health Sciences (NYSE:USNA – Get Free Report) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 2.450-2.450 for the period, compared to the consensus earnings per share estimate of 2.500. The company issued revenue guidance of $850.0 million-$850.0 million, compared to the consensus revenue estimate of $861.9 million.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on the company. DA Davidson reduced their target price on USANA Health Sciences from $38.00 to $35.00 and set a “neutral” rating for the company in a report on Wednesday. StockNews.com lowered shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 24th.
Read Our Latest Report on USNA
USANA Health Sciences Price Performance
USANA Health Sciences (NYSE:USNA – Get Free Report) last announced its earnings results on Tuesday, October 22nd. The company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.07. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.80%. The business had revenue of $200.22 million for the quarter, compared to the consensus estimate of $208.45 million. During the same period last year, the firm posted $0.59 earnings per share. On average, equities research analysts expect that USANA Health Sciences will post 2.5 earnings per share for the current fiscal year.
Insider Transactions at USANA Health Sciences
In other USANA Health Sciences news, insider Paul A. Jones sold 6,266 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total transaction of $240,489.08. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other USANA Health Sciences news, insider Paul A. Jones sold 6,266 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total transaction of $240,489.08. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director John Turman Fleming sold 1,000 shares of USANA Health Sciences stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total transaction of $44,430.00. Following the transaction, the director now directly owns 2,503 shares in the company, valued at $111,208.29. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 7,940 shares of company stock valued at $311,670. Insiders own 0.33% of the company’s stock.
About USANA Health Sciences
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Featured Articles
- Five stocks we like better than USANA Health Sciences
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How to Calculate Return on Investment (ROI)
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- The Downtrend in UPS Stock Isn’t Over Yet
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.